Vioxx: lessons for Health Canada and the FDA

January 2005
CMAJ: Canadian Medical Association Journal;1/4/2005, Vol. 172 Issue 1, p3
Academic Journal
Comments on the withdrawal of the COX-2 inhibitor rofecoxib from the market in September 2004 because of an increased risk of cardiovascular disease. Impact of revelations about the drug's risk on the market value of Merck & Co. Inc.; Critique of the drug approval policy; Shortcomings of the Food and Drug Administration and Health Canada on their public mandates.


Related Articles

  • FDA requests further data on Merck's Arcoxia application.  // PharmaWatch: CNS;December2004, Vol. 3 Issue 12, p16 

    Reports that the U.S. Food and Drug Administration has informed Merck & Co. that it will require further safety and efficacy information before granting approval of Merck's new drug application for the COX-2 inhibitor, Arcoxia. Company's revision of its new drug application to the agency to...

  • Vioxx.  // Formulary;May2004, Vol. 39 Issue 5, p235 

    Provides information on Merck & Co. Inc.'s cyclooxygenase-2 inhibitor Vioxx, or rofecoxib, which has been approved by the U.S. Food and Drug Administration for the treatment of migraine. Mechanism of action; Drug efficacy; Safety; Dosing.

  • Blow for Merck as FDA rejects Arcoxia.  // TCE: The Chemical Engineer;May2007, Issue 791, p5 

    The article reports that an advisory committee to the U.S. Food and Drug Administration (FDA) has recommended that Merck's cyclooxygenase-2 inhibitor, Etoricoxib, should not be approved. The committee pointed out that the risks associated with the drug, commonly known as Arcoxia, outweigh its...

  • Out of sight. McLaughlin, Neil // Modern Healthcare;10/18/2004, Vol. 34 Issue 42, p26 

    Focuses on the problems facing the pharmaceutical industry in the U.S. Recall of Vioxx cyclooxygenase 2 inhibitor by Merck & Co.; Flu vaccine debacle; Emergence of reports on price gouging.

  • A Painful Mistake. Gorman, Christine; Kher, Unmesh // Time;10/11/2004, Vol. 164 Issue 15, p48 

    This article discusses the impact of pharmaceutical giant, Merck, pulling its arthritis drug, Vioxx, off the market because of its health risks. A pharmaceutical company can rise and fall on the strength of a handful of blockbuster drugs, Vioxx was a giant. Unveiled with great fanfare by Merck...

  • Merck s Loss Could Turn Out to be Pfizer's Gain.  // Chemical Market Reporter;10/11/2004, Vol. 266 Issue 12, p12 

    Reports that Merck & Co.'s recall of the drug Vioxx (rofecoxib), a Cox-2 inhibitor, could actually boost the revenue at Pfizer Inc.. Confidence that patients will not abandon Cox-2 inhibitor drugs completely; Pfizer's competing Cox-2 inhibitors, Celebrex and Bextra; Patient safety concerns

  • Pharma Prophet. Herper, Matthew // Forbes Global;2/7/2005, Vol. 8 Issue 2, p60 

    Focuses on pharmacologist Garret FitzGerald and his views on Cox-2-inhibitor drugs from Merck and Pfizer. Forecast on the market performance of the drug; Drug companies affiliated with Fitzgerald; Side effects of the drugs.

  • In the face of CRISIS. Arnold, Matthew // Medical Marketing & Media;Feb2005, Vol. 40 Issue 2, p36 

    The article reports that the crisis over the safety of COX-2 inhibitors is almost certainly the most severe to hit the pharmaceutical industry in decades. At stake are the reputations not only of Merck & Co. Inc. and Pfizer Inc., whose corporate brands recently seemed armor plated, but of Big...

  • Vioxx withdrawal spurs rivals into action. McGuire, Stephen // Medical Marketing & Media;Nov2004, Vol. 39 Issue 11, p12 

    This article reports that in the wake of Merck & Co. Inc.'s decision to withdraw Vioxx because of unfavorable clinical trials data, Pfizer and Boehringer Ingelheim/ Abbot Laboratories' stepped up efforts to promote their respective rival COX- 2 inhibitors, Celebrex and Mobic. Merck had pulled...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics